2025
Novi G, Bovis F, Sciolla C, Frau J, Minetti M, Napoli F, Vianello M, Greco G, Sechi E, Bellomo A, Garelli P, Spiezia AL, Fantozzi R, Schirò G, Ghezzi L, Zecca C, Signoriello E, Brambilla L, Lucchini M, Bonavita S, Schiavetti I, Malentacchi M, Cocco E, Franceschini A, Mataluni G, Gastaldi M, Rolando A, Solla P, Cellerino M, Abbadessa G, Lanzillo R, Di Sapio A, Uccelli A, Sormani MP. (2025). Long-Term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder: A 5-Year Observational Study. CNS drugs, 10.1007/s40263-025-01191-7. Advance online publication. https://doi.org/10.1007/s40263-025-01191-7
Malucchi, S., Perini, P., Rinaldi, F., Radaelli, M., Malentacchi, M., Bertolotto, A., & Di Sapio, A. (2025). Disease Course in Patients Switched from Natalizumab to Alemtuzumab: An Italian Multicenter, Prospective, Observational Study. Neurology and therapy, 10.1007/s40120-025-00754-6. Advance online publication. https://doi.org/10.1007/s40120-025-00754-6
Centonze, D., Di Sapio, A., Brescia Morra, V., Colombo, E., Inglese, M., Paolicelli, D., Salvetti, M., & Furlan, R. (2025). Steps toward the implementation of neurofilaments in multiple sclerosis: patient profiles to be prioritized in clinical practice. Frontiers in neurology, 16, 1571605. https://doi.org/10.3389/fneur.2025.1571605
Mechelli R, Umeton R, Bellucci G, Bigi R, Rinaldi V, Angelini DF, Guerrera G, Pignalosa FC, Ilari S, Patrone M, Srinivasan S, Cerono G, Romano S, Buscarinu MC, Martire S, Malucchi S, Landi D, Lorefice L, Pizzolato Umeton R, Anastasiadou E, Trivedi P, Fornasiero A, Ferraldeschi M; IMSGC WTCCC2; Di Sapio A, Marfia G, Cocco E, Centonze D, Uccelli A, Di Silvestre D, Mauri P, de Candia P, D’Alfonso S, Battistini L, Farina C, Magliozzi R, Reynolds R, Baranzini SE, Matarese G, Salvetti M, Ristori G. (2025). A disease-specific convergence of host and Epstein-Barr virus genetics in multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 122(14), e2418783122. https://doi.org/10.1073/pnas.2418783122
2024
Bava CI, Valentino P, Malucchi S, Bottero R, Martire S, Sapio AD, Bertolotto A. Prevalence of elevated sNFL in a real-world setting: Results on 908 patients with different multiple sclerosis types and treatment conditions. Mult Scler Relat Disord. 2024 Jun 29;88:105748. doi: 10.1016/j.msard.2024.105748.
Malucchi S, Bava CI, Valentino P, Martire S, Lo Re M, Bertolotto A, Di Sapio A. In multiple sclerosis patients a single serum neurofilament light chain (sNFL) dosage is strongly associated with 12 months outcome: data from a real-life clinical setting. J Neurol. 2024 Dec;271(12):7494-7501. doi: 10.1007/s00415-024-12701-w. Epub 2024 Sep 23. PMID: 39313638.
Ponzio, M., Battaglia, M. A., Trojano, M., Salivetto, M., D’Ettorre, A., Corrado, D., Paletta, P., Lepore, V., Mosconi, P., Comitato Scientifico del Registro Italiano Sclerosi Multipla e Patologie Correlate, Rete dei centri del Registro Italiano Sclerosi Multipla e Patologie Correlate & Rete degli assistenti di ricerca del Registro Italiano Sclerosi Multipla e Patologie Correlate (2024). I registri come importante fonte di real world data: l’esperienza del Registro Italiano Sclerosi Multipla e Patologie Correlate [Registers as central real world data source: the experience of the Italian Multiple Sclerosis and Related Disorders Register]. Epidemiologia e prevenzione, 48(4-5), 361–374. https://doi.org/10.19191/EP24.4-5.A734.074
Chisari, C. G., Amato, M. P., Di Sapio, A., Foschi, M., Iaffaldano, P., Inglese, M., Fermo, S. L., Lugaresi, A., Lus, G., Mascoli, N., Montepietra, S., Pesci, I., Quatrale, R., Salemi, G., Torri Clerici, V., Totaro, R., Valentino, P., Filippi, M., & Patti, F. (2024). Active and non-active secondary progressive multiple sclerosis patients exhibit similar disability progression: results of an Italian MS registry study (ASPERA). Journal of neurology, 271(10), 6801–6810. https://doi.org/10.1007/s00415-024-12621-9
Paolicelli, D., Borriello, G., Clerici, R., Colombo, E., Croce, D., D’Amico, E., De Rossi, N., Di Sapio, A., Fenu, G., Maimone, D., Marfia, G. A., Moccia, M., Perini, P., Piscaglia, M. G., Razzolini, L., Riccaboni, M., Signoriello, E., Agostoni, G., Farina, A., Mondino, M., Tortorella, C. (2024). Predicted Expenditure for Prescription Drugs for Multiple Sclerosis in the Italian Market Between 2023 and 2028: Results of the Oracle Project. Neurology and therapy, 13(5), 1415–1430. https://doi.org/10.1007/s40120-024-00644-3
Iaffaldano, P., Lucisano, G., Guerra, T., Paolicelli, D., Portaccio, E., Inglese, M., Foschi, M., Patti, F., Granella, F., Romano, S., Cavalla, P., De Luca, G., Gallo, P., Bellantonio, P., Gallo, A., Montepietra, S., Di Sapio, A., Vianello, M., Quatrale, R., Spitaleri, D., Italian MS Register (2024). A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosis. Annals of clinical and translational neurology, 11(8), 2008–2015. https://doi.org/10.1002/acn3.52118
Maple, P. A., Tanasescu, R., Constantinescu, C. S., Valentino, P., Capobianco, M., D’Orso, S., Borsellino, G., Battistini, L., Ristori, G., Mechelli, R., Salvetti, M., & Gran, B. (2024). Cytomegalovirus, Epstein-Barr Virus, Herpes Simplex Virus, and Varicella Zoster Virus Infection Dynamics in People with Multiple Sclerosis from Northern Italy. Pathogens (Basel, Switzerland), 13(6), 499. https://doi.org/10.3390/pathogens13060499
Carta, S., Dinoto, A., Capobianco, M., Valentino, P., Montarolo, F., Sala, A., Reindl, M., Lo Re, M., Chiodega, V., Branger, P., Audoin, B., Aboab, J., Papeix, C., Collongues, N., Kerschen, P., Zephir, H., Créange, A., Bourre, B., Schanda, K., Flanagan, E. P., … Mariotto, S. (2024). Serum Biomarker Profiles Discriminate AQP4 Seropositive and Double Seronegative Neuromyelitis Optica Spectrum Disorder. Neurology(R) neuroimmunology & neuroinflammation, 11(1), e200188. https://doi.org/10.1212/NXI.0000000000200188
Iaffaldano, P., Lucisano, G., Guerra, T., Patti, F., Cocco, E., De Luca, G., Brescia Morra, V., Pozzilli, C., Zaffaroni, M., Ferraro, D., Gasperini, C., Salemi, G., Bergamaschi, R., Lus, G., Inglese, M., Romano, S., Bellantonio, P., Di Monte, E., Maniscalco, G. T., Conte, A., … Italian MS Register (2024). Evaluation of drivers of treatment switch in relapsing multiple sclerosis: a study from the Italian MS Registry. Journal of neurology, 271(3), 1150–1159. https://doi.org/10.1007/s00415-023-12137-8
2023
Vecchio, D., Puricelli, C., Malucchi, S., Virgilio, E., Martire, S., Perga, S., Passarelli, F., Valentino, P., Di Sapio, A., Cantello, R., Dianzani, U., & Comi, C. (2024). Serum and cerebrospinal fluid neurofilament light chains measured by SIMOA™, Ella™, and Lumipulse™ in multiple sclerosis naïve patients. Multiple sclerosis and related disorders, 82, 105412. https://doi.org/10.1016/j.msard.2023.105412
Valentino, P., Malucchi, S., Bava, C. I., Martire, S., Capobianco, M., Malentacchi, M., Sperli, F., Oggero, A., Di Sapio, A., & Bertolotto, A. (2023). Serum Neurofilaments are a reliable biomarker to early detect PML in Multiple Sclerosis patients. Multiple sclerosis and related disorders, 77, 104893. https://doi.org/10.1016/j.msard.2023.104893
Toscano, S., Oteri, V., Chisari, C. G., Finocchiaro, C., Lo Fermo, S., Valentino, P., Bertolotto, A., Zappia, M., & Patti, F. (2023). Cerebrospinal fluid neurofilament light chains predicts early disease-activity in Multiple Sclerosis. Multiple sclerosis and related disorders, 80, 105131. https://doi.org/10.1016/j.msard.2023.105131
Bruschi, N., Malentacchi, M., Malucchi, S., Sperli, F., Martire, S., Sala, A., Valentino, P., Bertolotto, A., Pautasso, M., & Capobianco, M. A. (2023). Tailoring Rituximab According to CD27-Positive B-Cell versus CD19-Positive B-Cell Monitoring in Neuromyelitis Optica Spectrum Disorder and MOG-Associated Disease: Results from a Single-Center Study. Neurology and therapy, 12(4), 1375–1383. https://doi.org/10.1007/s40120-023-00481-w
2022
Valentino P, Malucchi S, Martire S, Bava CI, Capobianco MA, Bertolotto A (2022). sNFL applicability as additional monitoring tool in natalizumab extended interval dosing regimen for RRMS patients. Mult Scler Relat Disord. 67:104176. doi: 10.1016/j.msard.2022.104176
Montarolo F, Martire S, Chiara F, Allegra S, De Francia S, Hoxha E, Tempia F, Capobianco MA, Bertolotto A. (2022) NURR1-deficient mice have age- and sex-specific behavioral phenotypes. J Neurosci Res. 100(9):1747-1754. doi: 10.1002/jnr.25067
Balbo I, Montarolo F, Genovese F, Tempia F, Hoxha E. (2022) Effects of the administration of Elovl5-dependent fatty acids on a spino-cerebellar ataxia 38 mouse model. Behav Brain Funct. 18(1):8. doi: 10.1186/s12993-022-00194-4
Martire S, Valentino P, Marnetto F, Mirabile L, Capobianco MA, Bertolotto A. (2022) The impact of pre-freezing storage time and temperature on gene expression of blood collected in EDTA tubes. Mol Biol Rep. doi: 10.1007/s11033-022-07320-5
Montarolo F, Martire S, Marnetto F, Valentino P, Valverde S, Capobianco MA, Bertolotto A. (2022) The Selective Agonist for Sphingosine-1-Phosphate Receptors Siponimod Increases the Expression Level of NR4A Genes in Microglia Cell Line. Curr. Issues Mol. Biol. 44, 1247-1256. https://doi.org/10.3390/cimb44030083
2021
Valentino P, Marnetto F, Martire S, Malucchi S, Bava CI, Popovic M, Bertolotto A (2021) Serum neurofilament light chain levels in healthy individuals: A proposal of cut-off values for use in multiple sclerosis clinical practice. MultSclerRelatDisord 54:103090. Jun.Doi: 10.1016/j.msard.2021.103090.
Furlan C, Montarolo F, Di Gregorio E, Parolisi R, Atlante S, Buffo A, Bertolotto A, Aime S, Gianolio E.J Analysis of the Gadolinium retention in the Experimental Autoimmune Encephalomyelitis (EAE) murine model of Multiple Sclerosis. Trace Elem Med Biol. 2021 Aug 2;68:126831. doi: 10.1016/j.jtemb.2021.126831. Online ahead of print. PMID: 34364067
Eriola Hoxha, Ilaria Balbo, Roberta Parolisi, Matteo Audano, Francesca Montarolo, Francesco Ravera, Michela Guglielmotto, Luisa Muratori, Stefania Raimondo, Eleonora Di Gregorio, Annalisa Buffo, Alfredo Brusco, Barbara Borroni, Nico Mitro, Donatella Caruso, Filippo Tempia (2021) Elovl5 is required for proper action potential conduction along peripheral myelinated fibers. Glia. 17 June 2021 https://doi.org/10.1002/glia.24048
Ilaria Balbo, Francesca Montarolo, Enrica Boda, Filippo Tempia and Eriola Hoxha (2021) Elovl5 Expression in the Central Nervous System of the Adult Mouse. Front. Neuroanat., 29 April 2021 doi.org/10.3389/fnana.2021.669073
Martire S, Montarolo F, Spadaro M, Perga S, Sforza M.L, Marozio L, Frezet F, Bruno S, Chiabotto G, Deregibus M.C, Camussi G, Botta G, Benedetto C, Bertolotto A (2021) A First Phenotypic and Functional Characterization of Placental Extracellular Vesicles from Womenwith Multiple Sclerosis. Int. J. Mol.Sci. 2021, 22, 2875. https://doi.org/10.3390/ijms22062875
Bandettini di Poggio M, Toni D, Gandolfo C, Paolicelli D, Zini A, Agostoni E, Bandini F, Ragno M, Altavista MC, Bertolotto A, Siciliano G, Vecchio M, Tambasco N, Gambardella A, Manganotti P, Melis M, Onofrj M, De Michele G, Reale N, Tedeschi G, Mancardi G. Coverage of the requirements of first and second level strokeunit in Italy. Neurol Sci. 2021 Mar;42(3):1073-1079. doi: 10.1007/s10072-020-04616-x.
Boffa G, Massacesi L, Inglese M, Mariottini A, Capobianco M, Lucia M, Amato MP, Cottone S, Gualandi F, De Gobbi M, Greco R, Scimè R, Frau J, Zimatore GB, Bertolotto A, Comi G, Uccelli A, Signori A, Angelucci E, Innocenti C, Ciceri F, Repice AM, Sormani MP, Saccardi R, Mancardi G; Italian BMT-MS studygroup. Long-Term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis. Neurology. 2021 Jan 20:10.1212/WNL.0000000000011461. doi: 10.1212/WNL.0000000000011461.
Capobianco M, Bertolotto A, Malucchi S. Fingolimod as first-line treatment in pediatric-onset multiple sclerosis: a case report. Neurol Sci. 2021 Mar 12. doi: 10.1007/s10072-020-05027-8.
Gnavi R, Picariello R, Alboini PE, Cavalla P, Grasso MF, Richiardi P, Bertolotto A, Barizzone N, Cantello R, Leone MA, D’Alfonso S, Golini N. Validation of an Algorithm to Detect Multiple Sclerosis Cases in Administrative Health Databases in Piedmont (Italy): An Application to the Estimate of Prevalence by Age and Urbanization Level. Neuroepidemiology. 2021 Mar 10:1-7. doi: 10.1159/000513763.
Lepore V, Bosetti C, Santucci C, Iaffaldano P, Trojano M, Mosconi P; Bertolotto A; Italian Multiple Sclerosis Register Centers Group, the Scientific Committee of Italian SM Register. Detection of disability worsening in relapsing-remitting multiple sclerosis patients: a real-world roving Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register. Eur J Neurol. 2021 Feb;28(2):567-578. doi: 10.1111/ene.14589. Epub 2020 Nov 6.
Sormani MP, De Rossi N, Schiavetti I, Carmisciano L, Cordioli C, Moiola L, Radaelli M, Immovilli P, Capobianco M, Trojano M, Zaratin P, Tedeschi G, Comi G, Battaglia MA, Patti F, Salvetti M; Bertolotto A. Musc-19 Study Group. Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. Ann Neurol. 2021 Apr;89(4):780-789. doi: 10.1002/ana.26028. Epub 2021 Feb 9.
2020
Masuccio FG, Lo Re M, Bertolotto A, Capobianco M, Solaro C. (2020). Benign SARS-CoV-2 infection in MOG-antibodies associated disorder during tocilizumab treatment. Mult Scler Relat Disord. Nov;46:102592. doi: 10.1016/j.msard.2020.102592. Epub 2020 Oct 21.
Perga S, Montarolo F, Martire S, Bonaldo B, Bono G, Bertolo J, Magliozzi R, Bertolotto A (2020) Overexpression of the ubiquitin-editing enzyme A20 in the brain lesions of Multiple Sclerosis patients: moving from systemic to central nervous system inflammation. Brain Pathology 14:e12906. Oct.DOI: 10.1111/bpa.12906. Online ahead of print.
Bandettini di Poggio M, Toni D, Gandolfo C, Paolicelli D, Zini A, Agostoni E, Bandini F, Ragno M, Altavista MC, Bertolotto A, Siciliano G, Vecchio M, Tambasco N, Gambardella A, Manganotti P, Melis M, Onofrj M, De Michele G, Reale N, Tedeschi G, Mancardi G. (2020) Coverage of the requirements of first and second level stroke unit in Italy. Neurol Sci. Jul 31. doi: 10.1007/s10072-020-04616-x. Online ahead of print.
Bertolotto A, Martire S, Mirabile L, Capobianco M, De Gobbi M, Cilloni D. (2020). Autologous Hematopoietic Stem Cell Transplantation (AHSCT): Standard of Care for Relapsing-Remitting Multiple Sclerosis Patients. Neurol Ther. Dec;9(2):197-203. doi: 10.1007/s40120-020-00200-9. Epub 2020 Jun 16.
Bertolotto A, Arroyo R, Celius EG, Comi G, Havrdova EK, Honeycutt WD, Hunter SF, Izquierdo G, Kornek B, Miller T, Mitsikostas DD, Singer BA, Ziemssen T, Chung L, Daizadeh N, Afsar S, Hashemi L, Senior P. (2020) Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies. Neurol Ther. Dec;9(2):443-457. doi: 10.1007/s40120-020-00191-7. Epub 2020 May 14.
Montarolo F*, Perga S, Tessarolo C, Spadaro M, Martire S, Bertolotto A (2020) TNFAIP3 Deficiency Affects Monocytes, Monocytes-Derived Cells and Microglia in Mice. International Journal of Molecular Science21, 2830. DOI:10.3390/ijms21082830
Comi G, Pozzilli C, Morra VB, Bertolotto A, Sangalli F, Prosperini L, Carotenuto A, Iaffaldano P, Capobianco M, Colombo D, Nica M, Rizzoli S, Trojano M. (2020) Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study. Neurol Sci. Oct;41(10):2843-2851. doi: 10.1007/s10072-020-04380-y. Epub 2020 Apr 21.
Valsecchi V*, Boido M*, Montarolo F, et al. The transcription factor Nurr1 is up-regulated in amyotrophic lateral sclerosis patients and SOD1-G93A mice [published online ahead of print, 2020 Mar 18]. Dis Model Mech. 2020;dmm.043513. doi:10.1242/dmm.043513 – *co-authors
Marangon D, Boda E, Parolisi R, Negri C, Giorgi C, Montarolo F, Perga S, Bertolotto A, Buffo A, Abbracchio MP, Lecca D. (2020) In vivo silencing of miR-125a-3p promotes myelin repair in models of white matter demyelination. Glia. Oct;68(10):2001-2014. doi: 10.1002/glia.23819. Epub 2020 Mar 12.
Giordano A, Testa S, Bassi M, Cilia S, Bertolotto A, Quartuccio ME, Pietrolongo E, Falautano M, Grobberio M, Niccolai C, Allegri B, Viterbo RG, Confalonieri P, Giovannetti AM, Cocco E, Grasso MG, Lugaresi A, Ferriani E, Nocentini U, Zaffaroni M, De Livera A, Jelinek G, Solari A, Rosato R. (2020) Assessing measurement invariance of MSQOL-54 across Italian and English versions. Qual Life Res. Mar;29(3):783-791. doi: 10.1007/s11136-019-02352-0. Epub 2019 Nov 9.
2019
Spadaro M, Montarolo F, Martire S., Frezet F, Bruno S, Grometto A, Perga S, Brescia F, Valentino P, Marnetto F, Botta G, Marozio L, Bertolotto A. Pregnancy: a powerful transient immunosuppressive phenomenon in Multiple Sclerosis women, Poster presentation at the 2019 FISM Congress, Rome (Italy).
Montarolo F, Martire S, Perga S and Bertolotto A. NURR1 Impairment in Multiple Sclerosis. Int. J. Mol. Sci. 2019, 20, 4858; doi:10.3390/ijms20194858.
Montarolo F, Perga S, Tessarolo C, Spadaro M, Martire S, Bertolotto A. TNFAIP3 in circulating and parenchymal myeloid lineage critically controls monocytes, monocytes-derived cells and microglia. Journal of Neuroinflammation (submitted).
Giordano A, Testa S, Bassi M, Cilia S, Bertolotto A, Quartuccio ME, Pietrolongo E, Falautano M, Grobberio M, Niccolai C, Allegri B, Viterbo RG, Confalonieri P, Giovannetti AM, Cocco E, Grasso MG, Lugaresi A, Ferriani E, Nocentini U, Zaffaroni M, De Livera A, Jelinek G, Solari A, Rosato R. Assessing measurement invariance of MSQOL-54 across Italian and English versions. Qual Life Res. 2019 Nov 9. doi: 10.1007/s11136-019-02352-0. [Epub ahead of print]
Acknowledgement to Authors, Referees and Readers 2019.
Sabbagh M, Bertolotto A. Neurol Ther. 2019 Dec;8(2):513-515. doi: 10.1007/s40120-019-00163-6. No abstract available.
Spadaro M, Martire S, Marozio L, Mastromauro D, Montanari E, Perga S, Montarolo F, Brescia F, Balbo A, Botta G, Benedetto C, Bertolotto A. Immunomodulatory Effect of Pregnancy on Leukocyte Populations in Patients With Multiple Sclerosis: A Comparison of Peripheral Blood and Decidual Placental Tissue.
Front Immunol. 2019 Aug 16;10:1935. doi: 10.3389/fimmu.2019.01935. eCollection 2019.
Montarolo F, Martire S, Perga S, Spadaro M, Brescia I, Allegra S, De Francia S, Bertolotto A. NURR1 deficiency is associated to ADHD-like phenotypes in mice. Transl Psychiatry. 2019 Aug 27;9(1):207. doi: 10.1038/s41398-019-0544-0.
Romano S, Ferraldeschi M, Bagnato F, Mechelli R, Morena E, Caldano M, Buscarinu MC, Fornasiero A, Frontoni M, Nociti V, Mirabella M, Mayer F, Bertolotto A, Pozzilli C, Vanacore N, Salvetti M, Ristori G. Drug Holiday of Interferon Beta 1b in Multiple Sclerosis: A Pilot, Randomized, Single Blind Study of Non-inferiority. Front Neurol. 2019 Jul 16;10:695. doi: 10.3389/fneur.2019.00695. eCollection 2019.
Barclay K, Carruthers R, Traboulsee A, Bass AD, LaGanke C, Bertolotto A, Boster A, Celius EG, de Seze J, Cruz DD, Habek M, Lee JM, Limmroth V, Meuth SG, Oreja-Guevara C, Pagnotta P, Vos C, Ziemssen T, Baker DP, Wijmeersch BV. Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings. Front Neurol. 2019 Mar 22;10:253. doi: 10.3389/fneur.2019.00253. eCollection 2019. Review.
Sabbagh M, Bertolotto A. Neurology and Therapy: Looking Back on 2018 and Forward to 2019.
Neurol Ther. 2019 Jun;8(1):1-3. doi: 10.1007/s40120-019-0126-3. Epub 2019 Jan 30. No abstract available.
2018
Scarpazza C, Signori A, Prosperini L, Sormani MP, Cosottini M, Capra R, Gerevini S. Italian PML Group. Early diagnosis of progressive multifocal leucoencephalopathy: longitudinal lesion evolution. 2018 ; J Neurol Neurosurg Psychiatry. 2018 Nov 2. IF 7.14 R=36/336
Prosperini L, Annovazzi P, Boffa L, Buscarinu MC, Gallo A, Matta M, Moiola L, Musu L, Perini P, Avolio C, Barcella V, Bianco A, Farina D, Ferraro E, Pontecorvo S, Granella F, Grimaldi LME, Laroni A, Lus G, Patti F, Pucci E, Pasca M, Sarchielli P; Italian Alemtuzumab Study Group. No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month realworld study. J Neurol. 2018 Sep 26. IF=3.78
Marcinnò A, Marnetto F, Valentino P, Martire S, Balbo A, Drago A, Leto M, Capobianco M, Panzica G, Bertolotto, A. Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders. Neurol Neuroimmunol Neuroinflamm. 2018 Sep 13;5(6) IF= 6.429; R= 36/336
Bo M, Charrier L, Bartalini S, Benvenuti M, Oggero A, Ulivelli M, Gabbrielli M, Bertolotto A, Gianino MM. Access to social security benefits among multiple sclerosis patients in Italy: A cross-sectional study Mult Scler Relat Disord. 2018 Aug; 24:107-112. IF=4.84¸ R=clinical neurology 91/336
Mallucci G, Annovazzi P, Miante S, Torri-Clerici V, Matta M, La Gioia S, Cavarretta R, Mantero V, Costantini G, D’Ambrosio V, Zaffaroni M, Ghezzi A, Perini P, Rossi S, Bertolotto A, Rottoli MR, Rovaris M, Balgera R, Cavalla P, Montomoli C, Bergamaschi R. Two-year real-life efficacy, tolerability and safety of dimethyl fumarate in an Italian multicentre study. J Neurol. 2018 Aug; 265(8):1850-1859. IF= 3.78
Rosato R, Testa S, Bertolotto A, Scavelli F, Giovannetti AM, Confalonieri P, Patti F, Chisari CG, Lugaresi A, Pietrolongo E, Grasso MG, Rossi I, Toscano A, Loera B, Giordano A, Solari A. eMSQOL-29: Prospective validation of the abbreviated, electronic version of MSQOL-54. Mult Scler. 2018 May IF= 5.28 R=69/336
Perga S, Martire S, Montarolo F, Giordani I, Spadaro M, Bono G, Corvisieri S, Messuti I, Panzica G, Orlandi F, Bertolotto A. The Footprints of Poly-Autoimmunity: Evidence for Common Biological Factors Involved in Multiple Sclerosis and Hashimoto’s Thyroiditis. Front Immunol. 2018 Feb 20; 9:311. IF= 6.429; R= 24/194
Carletto S, Borghi M, Scavelli F, Francone D, Perucchini ML, Cavallo M, Pagnini F, Bertolotto A, Oliva F, Ostacoli L. Prevalence of Posttraumatic Stress Disorder in Patients With Multiple Sclerosis. J Nerv Ment Dis. 2018 Feb;206(2):149-151. IF= 1.94 R= 167/487
Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A Baroncini D, Zaffaroni M, Moiola L, Lorefice L, Fenu G, Iaffaldano P, Simone M, Fanelli F, Patti F, D’Amico E, Capobianco M, Bertolotto A, Gallo P, Margoni M, Miante S, Milani N, Amato MP, Righini I, Bellantonio P, Scandellari C, Costantino G, Scarpini E, Bergamaschi R, Mallucci G, Comi G, Ghezzi A; iMED Registry and Gruppo di Studio SM-Società Italiana di Neurologia. multicentre, Italian, retrospective, observational study. Mult Scler. 2018 Jan 1 IF=5.28 R=69/336
Correction to: Management of pregnancy-related issues in multiple sclerosis patients: the need for an interdisciplinary approach. Amato MP, Bertolotto A, Brunelli R, Cavalla P, Goretti B, Marrosu MG, Patti F, Pozzilli C, Provinciali L, Rizzo N, Strobelt N, Tedeschi G, Trojano M, Comi G. Neurol Sci. 2018 Feb;39(2):395 IF=1.74; R=clinical neurology 169/336
Symptomatic cerebrospinal fluid HIV-1 escape with no resistance-associated mutations following low-level plasma viremia. Trunfio M, Joseph SB, Ghisetti V, Romito A, Martini C, Cusato J, Audagnotto S, Pesci Kincer L, Ferrara M, Sala A, Imperiale D, Di Perri G, Calcagno A. J Neurovirol. 2018 Feb;24(1):132-136 1 IF=3.22 R= 58/336
2017
Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med. 2017 Jan 19;376(3):209-220. doi: 10.1056/NEJMoa1606468.
Valentino P, Marnetto F, Granieri L, Capobianco M, Bertolotto A. Aquaporin-4 antibody titration in NMO patients treated with rituximab: A retrospective study. Neurol Neuroimmunol Neuroinflamm 2017;4:e317; doi: 10.1212/ NXI.0000000000000317 PMID: 28054001
Clemente N, Comi C, Raineri D, Cappellano G, Vecchio D, Orilieri E, Gigliotti CL, Boggio E, Dianzani C, Sorosina M, Martinelli-Boneschi F, Caldano M, Bertolotto A, Ambrogio L, Sblattero D, Cena T, Leone M, Dianzani U and Chiocchetti A (2017) Role of Anti-Osteopontin Antibodies in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis. Front. Immunol. 8:321. doi: 10.3389/fimmu.2017.00321
Melillo F, Di Sapio A, Martire S, Malentacchi M, Matta M, Bertolotto A. Computerized posturography is more sensitive than clinical Romberg Test in detecting postural control impairment in minimally impaired Multiple Sclerosis patients. Mult Scler and Rel Dis, 14:51-55, 2017 ISSN 2211-0348, http://doi.org/10.1016/j.msard.2017.03.008.
Malucchi S, Capobianco M, Lo Re M, Malentacchi M, di Sapio A, Matta M, Sperli F, Bertolotto A High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study. Neurol Ther. 2017 Jun;6(1):145-152. doi: 10.1007/s40120-016-0058-0. Epub 2016 Dec 3. PMID: 27915429
Landi D, De Rossi N, Zagaglia S, Scarpazza C, Prosperini L, Albanese M, Buttari F, Mori F, Marfia GA, Sormani MP, Capra R, Centonze D; Italian PML study group. Collaborators: Amato MP, Bandini F, Bertolotto A, Brescia-Morra V, Cavaletti G, Cavalla P, Capobianco M, Clerico M, D’Aleo G, de Riz M, Deotto L, Durelli L, Falcini M, Ferrari E, Fusco ML, Gasperini C, Gerevini S, Ghezzi A, Grimaldi L, Guidotti M, Lugaresi A, Naldi P, Moiola L, Perrone P, Pizzorno M, Pozzilli C, Rezzonico M, Rovaris M, Salemi G, Salvetti M, Santuccio G, Scarpini E, Sessa E, Solaro C, Tabiadon G, Tortorella C, Trojano M No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML. Neurology. 2017 Mar 21;88(12):1144-1152. doi: 10.1212/WNL.0000000000003740 PMID: 28228569
Marnetto F, Valentino P, Caldano M, Bertolotto A. Detection of potassium channel KIR4.1 antibodies in Multiple Sclerosis patients. J Immunol Methods. 2017 Mar 12. pii: S0022-1759(16)30395-7. doi: 10.1016/j.jim.2017.03.008. [Epub ahead of print] PMID: 28300540
Iaffaldano P, Simone M, Lucisano G, Ghezzi A, Coniglio G, Brescia Morra V, Salemi G, Patti F, Lugaresi A, Izquierdo G, Bergamaschi R, Cabrera-Gomez JA, Pozzilli C, Millefiorini E, Alroughani R, Boz C, Pucci E, Zimatore GB, Sola P, Lus G, Maimone D, Avolio C, Cocco E, Sajedi SA, Costantino G, Duquette P, Shaygannejad V, Petersen T, Fernández Bolaños R, Paolicelli D, Tortorella C, Spelman T, Margari L, Amato MP, Comi G, Butzkueven H, Trojano M; Italian iMedWeb Registry and the MSBase Registry. Prognostic indicators in pediatric clinically isolated syndrome. Ann Neurol. 2017 May;81(5):729-739. doi: 10.1002/ana.24938. PMID: 28439957
Spadaro M, Montarolo F, Perga S, Martire S, Brescia F, Malucchi S, Bertolotto A Biological activity of glatiramer acetate on Treg and anti-inflammatory monocytes persists for more than 10 years in responder multiple sclerosis patients Clin Immunol 181 (2017) 83–88 doi: 10.1016/j.clim.2017.06.006. PMID: 28642148
Gils A, Bertolotto A, Mulleman D, Bejan-Angoulvant T, Declerck PJ. Biopharmaceuticals: Reference Products and Biosimilars to Treat Inflammatory Diseases. Ther Drug Monit. 2017 Aug;39(4):308-315. doi: 10.1097/FTD.0000000000000385. PMID: 28230618
Paintaud G, Passot C, Ternant D, Bertolotto A, Bejan-Angoulvant T, Pascual-Salcedo D, Mulleman D. Rationale for Therapeutic Drug Monitoring of Biopharmaceuticals in Inflammatory Diseases. Ther Drug Monit. 2017 Aug;39(4):339-343. doi: 10.1097/FTD.0000000000000410. PMID: 28486309
Caldano M, Raoul W, Rispens T, Bertolotto A. Drug Efficacy Monitoring in Pharmacotherapy of Multiple Sclerosis With Biological Agents. Ther Drug Monit. 2017 Aug;39(4):350-355. doi: 10.1097/FTD.0000000000000393. PMID: 28328761
Carletto S, Tesio V, Borghi M, Francone D, Scavelli F, Bertino G, Malucchi S, Bertolotto A, Oliva F, Torta R, Ostacoli L. (2017) The Effectiveness of a Body-Affective Mindfulness Intervention for Multiple Sclerosis Patients with Depressive Symptoms: A Randomized Controlled Clinical Trial. Front Psychol. Nov 30;8:2083. IF= 2.32; R=33/129
Rocca MA, Sormani MP, Rovaris M, Caputo D, Ghezzi A, Montanari E, Bertolotto A, Laroni A, Bergamaschi R, Martinelli V, Comi G, Filippi M. (2017) Long-term disability progression in primary progressive multiple sclerosis: a 15-year study. Brain Nov 1;140(11):2814-2819.
Franciotta D, Gastaldi M, Sala A, Andreetta F, Rinaldi E, Ruggieri M, Leante R, Costa G, Biagioli T, Massacesi L, Bazzigaluppi E, Fazio R, Mariotto S, Ferrari S, Galloni E, Perini F, Zardini E, Zuliani L, Zoccarato M, Giometto B, Bertolotto A. (2017). Diagnostics of the neuromyelitis optica spectrum disorders (NMOSD). Neurol Sci. 2017 Oct;38(Suppl 2) Review.
Gastaldi M, Zardini E, Leante R, Ruggieri M, Costa G, Cocco E, De Luca G, Cataldo I, Biagioli T, Ballerini C, Castellazzi M, Fainardi E, Pettini P, Zaffaroni M, Giunti D, Capello E, Bernardi G, Ciusani E, Giannotta C, Nobile-Orazio E, Bazzigaluppi E, Passerini G, Bedin R, Sola P, Brivio R, Cavaletti G, Sala A, Bertolotto A, Desina G, Leone MA, Mariotto S, Ferrari S, Paternoster A, Giavarina D, Lolli F, Franciotta D. (2017). Cerebrospinal fluid analysis and the determination of oligoclonal bands. Neurol Sci. Oct;38(Suppl 2):217-22. Review
Ghezzi A, Bianchi A, Baroncini D, Bertolotto A, Malucchi S, Bresciamorra V, Lanzillo R, Milani N, Martinelli V, Patti F, Chisari C, Rottoli M, Simone M, Paolicelli D, Visconti A; FUTURE Study Group. (2017). A multicenter, observational, prospective study of self- and parent-reported quality of life in adolescent multiple sclerosis patients self-administering interferon-β1a using RebiSmart™-the FUTURE study. Neurol Sci. Nov;38(11):1999-2005.
Amato MP, Bertolotto A, Brunelli R, Cavalla P, Goretti B, Marrosu MG, Patti F, Pozzilli C, Provinciali L, Rizzo N, Strobelt N, Tedeschi G, Trojano M, Comi G. (2017). Management of pregnancy-related issues in multiple sclerosis patients: the need for an interdisciplinary approach. Neurol Sci. Oct;38(10) Erratum in: Neurol Sci. 2017 Dec 26
Annovazzi P, Bertolotto A, Brescia Morra V, Gasperini C, Montanari E, Navarra P, Patti F, Sormani MP, Ghezzi A. (2017) A Comprehensive Review on Copemyl®. Neurol Ther.Dec;6(2):161-173. Review R=94/138
2016
Bertolotto A, Malentacchi M, Capobianco M, di Sapio A, Malucchi S, Motuzova Y, Pulizzi A, Berchialla P, Sperli F The use of the 25 Sprotte needle markedly reduces post-dural puncture headache in routine neurological practice Cephalalgia 2016, 36: 131-138, doi:10.1177/0333102415583983
Carletto S, Borghi M, Francone D, Scavelli F, Bertino G, Cavallo M, Malucchi S, Bertolotto A, Oliva F, Ostacoli L. The efficacy of a Mindfulness Based Intervention for depressive symptoms in patients with Multiple Sclerosis and their caregivers: study protocol for a randomized controlled clinical trial. BMC Neurol. 2016 Jan 13;16(1):7. doi: 10.1186/s12883-016-0528-0. ISSN: 14712377 PMID: 26757728
Martire S, Navone ND, Montarolo F, Perga S, Bertolotto A. A gene expression study denies the ability of 25 candidate biomarkers to predict the interferon-beta treatment response in multiple sclerosis patients. J Neuroimmunol. 2016 Mar 15;292:34-9. doi: 10.1016/j.jneuroim.2016.01.010. Epub 2016 Jan 16. PMID: 26943956
Lublin F, Miller DH, Freedman MS, Cree BA, Wolinsky JS, Weiner H, Lubetzki C, Hartung HP, Montalban X, Uitdehaag BM, Merschhemke M, Li B, Putzki N, Liu FC, Häring DA, Kappos L; INFORMS study investigators. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2016 Mar 12;387(10023):1075-84. doi: 10.1016/S0140-6736(15)01314-8. Epub 2016 Jan 28
Rosato R, Testa S, Bertolotto A, Confalonieri P, Patti F, Lugaresi A, Grasso MG, Toscano A, Giordano A, Solari A. Development of a Short Version of MSQOL-54 Using Factor Analysis and Item Response Theory. PLoS One. 2016 Apr 14;11(4):e0153466. doi: 10.1371/journal.pone.0153466. eCollection 2016. PMID: 27078146
Hegen H, Adrianto I, Lessard CJ, Millonig A, Bertolotto A, Comabella M, Giovannoni G, Guger M, Hoelzl M, Khalil M, Fazekas F, Killestein J, Lindberg RL, Malucchi S, Mehling M, Montalban X, Rudzki D, Schautzer F, Sellebjerg F, Sorensen PS, Deisenhammer F, Steinman L, Axtell RC. Cytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patients. Neurol Neuroimmunol Neuroinflamm. 2016 Jan 27;3(2):e202. doi: 10.1212/NXI.0000000000000202. eCollection 2016 Apr PMID: 26894205
Troni W, Melillo F, Bertolotto A, Malucchi S, Capobianco M, Sperli F, Di Sapio A. Normative Values for Intertrial Variability of Motor Responses to Nerve Root and Transcranial Stimulation: A Condition for Follow-Up Studies in Individual Subjects PLoS One. 2016 May 16;11(5):e0155268. doi: 10.1371/journal.pone.0155268. eCollection 2016. PMID: 27182973
Borghi M, Carletto S, Ostacoli L, Scavelli F, Pia L, Pagani M, Bertolotto A, Malucchi S, Signori A, Cavallo M. Decline of Neuropsychological Abilities in a Large Sample of Patients with Multiple Sclerosis: A Two-Year Longitudinal Study. Front Hum Neurosci. 2016 Jun 8;10:282. doi: 10.3389/fnhum.2016.00282. eCollection 2016. PMID: 27375468
Schwab N, Schneider-Hohendorf T, Pignolet B, Spadaro M, Görlich D, Meinl I, Windhagen S, Tackenberg B, Breuer J, Cantó E, Kümpfel T, Hohlfeld R, Siffrin V, Luessi F, Posevitz-Fejfár A, Montalban X, Meuth SG, Zipp F, Gold R, Du Pasquier RA, Kleinschnitz C, Jacobi A, Comabella M, Bertolotto A, Brassat D, Wiendl H. PML risk stratification using anti-JCV antibody index and L-selectin. Mult Scler. 2016 Jul;22(8):1048-1060. Epub 2015 Oct 2. PMID: 26432858
Lanzillo R, Quarantelli M, Pozzilli C, Trojano M, Amato MP, Marrosu MG, Francia A, Florio C, Orefice G, Tedeschi G, Bellantonio P, Annunziata P, Grimaldi LM, Comerci M, Brunetti A, Bonavita V, Alfano B, Marini S, Brescia Morra V; ARIANNA study group. No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon β1a therapy in relapsing-remitting multiple sclerosis (the ARIANNA study). Mult Scler. 2016 Aug;22(9):1163-73. doi: 10.1177/1352458515611222. Epub 2015 Oct 14. PMID: 26466947
Waters P, Reindl M, Saiz A, Schanda K, Tuller F, Kral V, Nytrova P, Sobek O, Nielsen HH, Barington T, Lillevang ST, Illes Z, Rentzsch K, Berthele A, Berki T, Granieri L, Bertolotto A, Giometto B, Zuliani L, Hamann D, van Pelt ED, Hintzen R, Höftberger R, Costa C, Comabella M, Montalban X, Tintoré M, Siva A, Altintas A, Deniz G, Woodhall M, Palace J, Paul F, Hartung HP, Aktas O, Jarius S, Wildemann B, Vedeler C, Ruiz A, Leite MI, Trillenberg P, Probst M, Saschenbrecker S, Vincent A, Marignier R. Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. J Neurol Neurosurg Psychiatry. 2016 Sep;87(9):1005-15. doi: 10.1136/jnnp-2015-312601. PMID: 27113605
Patti F, Messina S, Solaro C, Amato MP, Bergamaschi R, Bonavita S, Bruno Bossio R, Brescia Morra V, Costantino GF, Cavalla P, Centonze D, Comi G, Cottone S, Danni M, Francia A, Gajofatto A, Gasperini C, Ghezzi A, Iudice A, Lus G, Maniscalco GT, Marrosu MG, Matta M, Mirabella M, Montanari E, Pozzilli C, Rovaris M, Sessa E, Spitaleri D, Trojano M, Valentino P, Zappia M; SA.FE. study group. Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity. J Neurol Neurosurg Psychiatry. 2016 Sep;87(9):944-51. doi: 10.1136/jnnp-2015-312591. Epub 2016 May 9. PMID: 27160523
Montarolo F, Perga S, Martire S, Navone DN, Marchet A, Leotta D, Bertolotto A. Altered NR4A Subfamily Gene Expression Level in Peripheral Blood of Parkinson’s and Alzheimer’s Disease Patients. Neurotox Res. 2016 Oct;30(3):338-44. doi: 10.1007/s12640-016-9626-4. Epub 2016 May 9. PMID: 27159982
Giovannoni G, Cohen JA, Coles AJ, Hartung HP, Havrdova E, Selmaj KW, Margolin DH, Lake SL, Kaup SM, Panzara MA, Compston DA; CARE-MS II Investigators. Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients. Neurology. 2016 Nov 8;87(19):1985-1992. PMID: 27733571
Arnold DL, Fisher E, Brinar VV, Cohen JA, Coles AJ, Giovannoni G, Hartung HP, Havrdova E, Selmaj KW, Stojanovic M, Weiner HL, Lake SL, Margolin DH, Thomas DR, Panzara MA, Compston DA; CARE-MS I and CARE-MS II Investigators. Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS. Neurology 2016 Oct 4;87(14):1464-1472 PMID: 27590291 PMCID: PMC5075976 DOI: 10.1212/WNL.0000000000003169
Chiavazza C, Cistaro A, Fania P, Bertolotto A, Cavalla P, Rudà R, Pinessi L, Soffietti R Reversible disconnection syndrome in a case of acute tumefactive demyelinating lesion: a PET study. Neurol Sci. 2016 Dec;37(12):2019-2023 PMID: 27457655
Marola S, Ferrarese A, Gibin E, Capobianco M, Bertolotto A, Enrico S, Solej M, Martino V, Destefano I, Nan. o M. Anal sphincter dysfunction in multiple sclerosis: an observation manometric study. Open Med. 2016; 11: 509-517DOI 10.1515/med-2016-0088
2015
Chiò A, Calvo A, Moglia C, Canosa A, Brunetti M, Barberis M, Restagno G, Conte A, Bisogni G, Marangi G, Moncada A, Lattante S, Zollino M, Sabatelli M, Bagarotti A, Corrado L, Mora G, Bersano E, Mazzini L, D’Alfonso S; For PARALS; ATXN2 polyQ intermediate repeats are a modifier of ALS survival. Neurology. 2015 Jan 20;84(3):251-8. doi: 10.1212/WNL.0000000000001159. Epub 2014 Dec 19. PMID: 25527265
Motuzova Y, Di Sapio A, Capobianco M, Sala A, Marnetto F, Malucchi S, Bertolotto A Peculiar cytological CSF pattern in a case of encephalomyelitis during anti-TNF-alfa therapy. Neurol Ther. 2015 Jun;4(1):53-60. doi: 10.1007/s40120-015-0027-z
Capobianco M, Lo Re M, Sangalli F, Moiola L, Perini P, Gallo P, Danni M, Provinciali L, Repice A, Massacesi L, Messina S, Patti F, Laroni A, Mancardi GL, Pucci E, Calabrese M, Bertolotto A. (2015) Cyclophosphamide Pulses Therapy after Natalizumab Discontinuation for Multiple Sclerosis: A Multicentre Study. J Mult Scler (Foster City) 2:151.doi:10.4172/2376- 0389.1000151
Roppolo, M, Mulasso A, Gollin, M, Bertolotto, A, Rabaglietti, E. Physical exercise and psychological health in women with Multiple Sclerosis: The moderating effect of the disability level [Esercizio fisico e salute psicologica in donne affette da Sclerosi Multipla: L’Effetto di moderazione del livello di disabilità] Psicologia della Salute 3:5-23, 2015 DOI: 10.3280/PDS2015-003001
Lo Re M, Capobianco M, Ragonese P, Realmuto S, Malucchi S, Berchialla P, Salemi G, Bertolotto A. Natalizumab Discontinuation and Treatment Strategies in Patients with Multiple Sclerosis (MS): A Retrospective Study from Two Italian MS Centers. Neurol Ther. 2015 Dec;4(2):147-57. doi: 10.1007/s40120-015-0038-9. Epub 2015 Dec 8. PMID: 26647006
Lanzillo R, Quarantelli M, Pozzilli C, Trojano M, Amato MP, Marrosu MG, Francia A, Florio C, Orefice G, Tedeschi G, Bellantonio P, Annunziata P, Grimaldi LM, Comerci M, Brunetti A, Bonavita V, Alfano B, Marini S, Brescia Morra V; ARIANNA study group. (2015) No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon β1a therapy in relapsing-remitting multiple sclerosis (the ARIANNA study). Mult Scler. Oct 14
Schwab N, Schneider-Hohendorf T, Pignolet B, Spadaro M, Görlich D, Meinl I, Windhagen S, Tackenberg B, Breuer J, Cantó E, Kümpfel T, Hohlfeld R, Siffrin V, Luessi F, Posevitz-Fejfár A, Montalban X, Meuth SG, Zipp F, Gold R, Du Pasquier RA, Kleinschnitz C, Jacobi A, Comabella M, Bertolotto A, Brassat D, Wiendl H.(2015) PML risk stratification using anti-JCV antibody index and L-selectin.Mult Scler. Oct 2.
Iaffaldano P, Lucisano G, Pozzilli C, Brescia Morra V, Ghezzi A, Millefiorini E, Patti F, Lugaresi A, Zimatore GB, Marrosu MG, Amato MP, Bertolotto A, Bergamaschi R, Granella F, Coniglio G, Tedeschi G, Sola P, Lus G, Ferrò MT, Iuliano G, Corea F, Protti A, Cavalla P, Guareschi A, Rodegher M, Paolicelli D, Tortorella C, Lepore V, Prosperini L, Saccà F, Baroncini D, Comi G, Trojano M; Italian iMed-Web database. (2015) Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.Brain. Nov;138(Pt 11):3275-86.
Montarolo F, Perga S, Martire S, Bertolotto A. (2015) Nurr1 reduction influences the onset of chronic EAE in mice.Inflamm Res. Nov;64(11):841-4.
Spadaro M, Caldano M, Marnetto F, Lugaresi A, Bertolotto A. (2015) Natalizumab treatment reduces L-selectin (CD62L) in CD4+ T cells.J Neuroinflammation. Aug 12;12:146.
Veroni C, Marnetto F, Granieri L, Bertolotto A, Ballerini C, Repice AM, Schirru L, Coghe G, Cocco E, Anastasiadou E, Puopolo M, Aloisi F. (2015) Immune and Epstein-Barr virus gene expression in cerebrospinal fluid and peripheral blood mononuclear cells from patients with relapsing-remitting multiple sclerosis.J Neuroinflammation. Jul 14;12:132.
Perga S, Giuliano Albo A, Lis K, Minari N, Falvo S, Marnetto F, Caldano M, Reviglione R, Berchialla P, Capobianco MA, Malentacchi M, Corpillo D, Bertolotto A. (2015) Vitamin D Binding Protein Isoforms and Apolipoprotein E in Cerebrospinal Fluid as Prognostic Biomarkers of Multiple Sclerosis.PLoS One. Jun 5;10(6)
Bertolotto A, Malentacchi M, Capobianco M, di Sapio A, Malucchi S, Motuzova Y, Pulizzi A, Berchialla P, Sperli F. (2015) The use of the 25 Sprotte needle markedly reduces post-dural puncture headache in routine neurological practice.Cephalalgia. Apr 23.
Bertolotto A. (2015) Evaluation of the impact of neutralizing antibodies on IFNβ response.Clin Chim Acta. Sep 20;449:31-6.
Rosato R, Testa S, Oggero A, Molinengo G, Bertolotto A. (2015) Quality of life and patient preferences: identification of subgroups of multiple sclerosis patients.Qual Life Res. Sep;24(9):2173-82.
Prosperini L, Annovazzi P, Capobianco M, Capra R, Buttari F, Gasperini C, Galgani S, Solaro C, Centonze D, Bertolotto A, Pozzilli C, Ghezzi A. (2015) Natalizumab discontinuation in patients with multiple sclerosis: Profiling risk and benefits at therapeutic crossroads.Mult Scler. Nov;21(13):1713-22.
Perga S, Montarolo F, Martire S, Berchialla P, Malucchi S, Bertolotto A. (2015) Anti-inflammatory genes associated with multiple sclerosis: a gene expression study.J Neuroimmunol. Feb 15;279:75-8.
Bertolotto A, Granieri L, Marnetto F, Valentino P, Sala A, Capobianco M, Malucchi S, Di Sapio A, Malentacchi M, Matta M, Caldano M. (2015) Biological monitoring of IFN-β therapy in Multiple Sclerosis.Cytokine Growth Factor Rev. Apr;26(2):241-8.
Lo Re M, di Sapio A, Malentacchi M, Granieri L, Bertolotto A. (2015) Acute confusional state in HaNDL syndrome (transient headache and neurologic deficits with cerebrospinal fluid lymphocytosis).Neurol Sci. Mar;36(3):477-8.
Capobianco M, di Sapio A, Malentacchi M, Malucchi S, Matta M, Sperli F, Bertolotto A. (2015) No impact of current therapeutic strategies on disease reactivation after natalizumab discontinuation: a comparative analysis of different approaches during the first year of natalizumab discontinuation.Eur J Neurol. Mar;22(3):585-7
Yana Motuzova, Alessia Di Sapio, Marco Capobianco, Arianna Sala, Fabiana Marnetto, Simona Malucchi, Antonio Bertolotto. Peculiar Cytological Cerebrospinal Fluid Pattern in a Case of Encephalomyelitis During Anti-Tumor Necrosis Factor-a Therapy. (2015) Neurol Ther 4:53–60
2014
Bertolotto A, Capobianco M, Amato MP, Capello E, Capra R, Centonze D, Di Ioia M, Gallo A, Grimaldi L, Imberti L, Lugaresi A, Mancinelli C, Marrosu MG, Moiola L, Montanari E, Romano S, Musu L, Paolicelli D, Patti F, Pozzilli C, Rossi S, Salvetti M, Tedeschi G, Tola MR, Troiano M, Zaffaroni M, Malucchi S; Italian Multiple Sclerosis Study group (2014). Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group. Neurol Sci 35(2):307-16
Capobianco M, Piccoli G, Neve Vigotti F, Scapoli P, Deagostini MC, Albera C, Roccatello D, Bertolotto A (2014). Interferon beta-related nephropathy and interstitial lung disease: a new association and a long-term warning. Mult Scler
Di Battista G, Bertolotto A, Gasperini C, Ghezzi A, Maimone D, Solaro C (2014). Multiple Sclerosis State of the Art (SMART): A Qualitative and Quantitative Analysis of Therapy’s Adherence, Hospital Reliability’s Perception, and Services Provided Quality. Mult Scler Int 2014:752318
Di Sapio A, Bertolotto A, Melillo F, Sperli F, Malucchi S, Troni W (2014). A new neurophysiological approach to assess central motor conduction damage to proximal and distal muscles of lower limbs. Clin Neurophysiol 125(1):133-41
Gnanapavan S, Hegen H, Khalil M, Hemmer B, Franciotta D, Hughes S, Hintzen R, Jeromin A, Havrdova E, Tumani H, Bertolotto A, Comabella M, Frederiksen J,Alvarez-Cermeño JC, Villar L, Galimberti D, Myhr KM, Dujmovic I, Fazekas F, Ionete C, Menge T, Kuhle J, Keir G, Deisenhammer F, Teunissen C, Giovannoni G (2014). Guidelines for uniform reporting of body fluid biomarker studies in neurologic disorders. Neurology 83(13):1210-1216
Hegen H, Millonig A, Bertolotto A, Comabella M, Giovanonni G, Guger M, Hoelzl M, Khalil M, Killestein J, Lindberg R, Malucchi S, Mehling M, Montalban X, Polman CH, Rudzki D, Schautzer F, Sellebjerg F, Sørensen PS, Deisenhammer F (2014). Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development. Mult Scler 20(5):577-87
Marnetto F, Granieri L, Valentino P, Capobianco M, Pautasso M, Bertolotto A (2014). CD19 mRNA quantification improves rituximab treatment-to-target approach: A proof of concept study. J Neuroimmunol [Epub ahead of print]
Montarolo F, Raffaele C, Perga S, Martire S, Finardi A, Furlan R, Hintermann S, Bertolotto A (2014). Effects of isoxazolo-pyridinone 7e, a potent activator of the nurr1 signaling pathway, on experimental autoimmune encephalomyelitis in mice. PLoS One 9(9):e108791
Navone ND, Perga S, Martire S, Berchialla P, Malucchi S, Bertolotto A (2014). Monocytes and CD4+ T cells contribution to the under-expression of NR4A2 and TNFAIP3 genes in patients with multiple sclerosis. J Neuroimmunol 272(1-2):99-102
2013
Comi G, Battaglia M, Bertolotto A, Sette MD, Ghezzi A, Malferrari G, Salvetti M, Sormani M, Tesio L, Stolz E, Zaratin P, Mancardi G; CoSMo Collaborative Study Group.Observational case-control study of the prevalence of chronic cerebrospinal venous insufficiency in multiple sclerosis: results from the CoSMo study. Mult Scler. 2013 Oct;19(11):1508-17. doi: 10.1177/1352458513501231
Hegen H, Millonig A, Bertolotto A, Comabella M, Giovanonni G, Guger M, Hoelzl M, Khalil M, Killestein J, Lindberg R, Malucchi S, Mehling M, Montalban X, Polman C, Rudzki D, Schautzer F, Sellebjerg F, Sørensen P, Deisenhammer F. Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development. Mult Scler. 2013 Sep 5
Borghi M, Cavallo M, Carletto S, Ostacoli L, Zuffranieri M, Picci RL, Scavelli F, Johnston H, Furlan PM, Bertolotto A, Malucchi S. Presence and significant determinants of cognitive impairment in a large sample of patients with multiple sclerosis. PLoS One. 2013 Jul 29;8(7):e69820. doi: 10.1371/journal.pone.0069820
Di Sapio A, Bertolotto A, Melillo F, Sperli F, Malucchi S, Troni W. A new neurophysiological approach to assess central motor conduction damage to proximal and distal muscles of lower limbs. Clin Neurophysiol. 2013 Jul 15. doi:pii: S1388-2457(13)00737-2. 10.1016/j.clinph.2013.06.018
Teunissen C, Menge T, Altintas A, Alvarez-Cermeño JC, Bertolotto A, Berven FS, Brundin L, Comabella M, Degn M, Deisenhammer F, Fazekas F, Franciotta D, Frederiksen JL, Galimberti D, Gnanapavan S, Hegen H, Hemmer B, Hintzen R, Hughes S, Iacobaeus E, Kroksveen AC, Kuhle J, Richert J, Tumani H, Villar LM, Drulovic J, Dujmovic I, Khalil M, Bartos A. Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis. Mult Scler J 2013 May 21. [Epub ahead of print]
Comi G, Battaglia MA, Bertolotto A, Del Sette M, Ghezzi A, Malferrari G, Salvetti M, Sormani MP, Tesio L, Stolz E, Mancardi G. Italian multicentre observational study of the prevalence of CCSVI in multiple sclerosis (CoSMo study): rationale, design, and methodology. Neurol Sci. 2013 Aug;34(8):1297-307. doi: 10.1007/s10072-012-1269-5
Ostacoli L, Carletto S, Borghi M, Cavallo M, Rocci E, Zuffranieri M, Malucchi S, Bertolotto A, Zennaro A, Furlan PM, Picci RL. Prevalence and significant determinants of post-traumatic stress disorder in a large sample of patients with multiple sclerosis. J Clin Psychol Med Settings. 2013 Jun;20(2):240-6. doi: 10.1007/s10880-012-9323-2
Ghezzi A, Annovazzi P, Cocco E, Coarelli G, Lugaresi A, Rovaris M, Patti F, Capello E, Rodegher ME, Moiola L, Malucchi S, Salemi G, De Rossi N, Provinciali L, Perini P, Bergamaschi R, Scarpini E, Lus G, Gallo A, Tola MR, Amato MP, Rottoli MR, Bianchi A, Comi G; MS Study Group-Italian Society of Neurology. Endovascular treatment of CCSVI in patients with multiple sclerosis: clinical outcome of 462 cases. Neurol Sci. 2013 Sep;34(9):1633-7. doi: 10.1007/s10072-013-1300-5
Annovazzi P, Tomassini V, Bodini B, Boffa L, Calabrese M, Cocco E, Cordioli C, De Luca G, Frisullo G, Gallo A, Malucchi S, Paolicelli D, Pesci I, Radaelli M, Ragonese P, Roccatagliata L, Tortorella C, Vercellino M, Zipoli V, Gasperini C, Rodegher M, Solaro C. A cross-sectional, multicentre study of the therapeutic management of multiple sclerosis relapses in Italy. Neurol Sci. 2013 Feb;34(2):197-203. doi: 10.1007/s10072-012-0981-5
2012
Granieri L, Marnetto F, Valentino P, Frau J, Patanella AK, Nytrova P, Sola P, Capobianco M, Jarius S, Bertolotto A. (2012) Evaluation of a multiparametric immunofluorescence assay for standardization of neuromyelitis optica serology. PLoS One 7(6):e38896.
Gilli F, Navone ND, Valentino P, Granieri L, Perga S, Malucchi S, Bertolotto A (2012) Classification of individuals based on ex-vivo glatiramer acetate-induced interferon-? and interleukin-4 response. Mult Scler 18(10):1484-92.
Sørensen PS, Bertolotto A, Edan G, Giovannoni G, Gold R, Havrdova E, Kappos L, Kieseier BC, Montalban X, Olsson T. (2012) Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler. 18(2):143-52. Review.
Del Campo M, Mollenhauer B, Bertolotto A, Engelborghs S, Hampel H, Simonsen AH, Kapaki E, Kruse N, Le Bastard N, Lehmann S, Molinuevo JL, Parnetti L, Perret-Liaudet A, Sáez-Valero J, Saka E, Urbani A, Vanmechelen E, Verbeek M, Visser PJ, Teunissen C (2012) Recommendations to standardize preanalytical confounding factors in Alzheimer’s and Parkinson’s disease cerebrospinal fluid biomarkers: an update. Biomark Med 6:419-30. doi: 10.2217/bmm.12.46. PubMed PMID: 22917144.
Laroni A, Giacomazzi CG, Grimaldi L, Gallo P, Sormani MP, Bertolotto A, McDermott JL, Gandoglia I, Martini I, Vitello G, Rinaldi F, Barzon L, Militello V, Pizzorno M, Bandini F, Capello E, Palù G, Uccelli A, Mancardi GL, Varnier OE (2012) Urinary JCV-DNA testing during natalizumab treatment may increase accuracy of PML risk stratification. J Neuroimmune Pharmacol 7:665-72. doi: 10.1007/s11481-012-9366-z. Epub 2012 May 16. PubMed PMID: 2258541
Sørensen PS, Bertolotto A, Edan G, Giovannoni G, Gold R, Havrdova E, Kappos L, Kieseier BC, Montalban X, Olsson T (2012) Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler 18:143-52. Review. PubMed PMID: 22312009.
Mancardi GL, Sormani MP, Di Gioia M, Vuolo L, Gualandi F, Amato MP, Capello E, Currò D, Uccelli A, Bertolotto A, Gasperini C, Lugaresi A, Merelli E, Meucci G, Motti L, Tola MR, Scarpini E, Repice AM, Massacesi L, Saccardi R; Italian BMT Study Group (2012) Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience. Mult Scler 18:835-42. Epub 2011 Nov 29. PubMed PMID: 22127896.
Capobianco M, Motuzova Y, Frau J, Cocco E, Mamusa E, Marrosu MG, Bertolotto A (2012) Natalizumab i aggressive multiple sclerosis after haematopoietic stem cell transplantation. Neurol Sci 33:863-7. Epub 2011 Nov 25. PubMed PMID: 22116203.
2011
Van Beers MM, Gilli F, Schellekens H, Randolph TW, Jiskoot W (2011) Immunogenicity of recombinant human interferon beta interacting with particles of glass, metal, and polystyrene. J Pharm Sci 2012 Jan;101:187-99. doi: 10.1002/jps.22744. Epub 2011 Sep 14
Van Beers MM, Gilli F, Schellekens H, Randolph TW, Jiskoot W (2011). Immunogenicity of recombinant human interferon beta interacting with particles of glass, metal, and polystyrene. J Pharm Sci 2012 Jan;101:187-99. doi: 10.1002/jps.22744. Epub 2011 Sep 14
Van Beers MM, Sauerborn M, Gilli F, Brinks V, Schellekens H, Jiskoot W (2011). Oxidized and aggregated recombinant human interferon beta is immunogenic in human interferon beta transgenic mice. Pharm Res 28:2393-402
Gilli F, Navone ND, Perga S, Marnetto F, Caldano M, Capobianco M, Pulizzi A, Malucchi S, Bertolotto A (2011). Loss of braking signals during inflammation: a factor affecting the development and disease course of multiple sclerosis. Arch Neurol 68:879-88
Malucchi S, Gilli F, Caldano M, Sala A, Capobianco M, di Sapio A, Granieri L, Bertolotto A (2011). One-year evaluation of factors affecting the biological activity of interferon beta in multiple sclerosis patients. J Neurol 258:895-903
2010
Robotti A, Natale M, Albo AG, Lis K, Perga S, Marnetto F, Gilli F, Bertolotto A.(2010) Acute-phase proteins investigation based on lectins affinity capture prior to 2-DE separation: application to serum from multiple sclerosis patients.Electrophoresis 31(17):2882-93.
Polman CH, Bertolotto A, Deisenhammer F, Giovannoni G, Hartung HP, Hemmer B, Killestein J, McFarland HF, Oger J, Pachner AR, Petkau J, Reder AT, Reingold SC, Schellekens H, Sørensen PS. (2010) Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol 9(7):740-50.
Gilli F. (2010) Role of differential expression of IFN receptor isoforms on the response of MS patients to therapy with IFNbeta. J Interferon Cytokine Res. J Interferon Cytokine Res. 2010 Oct;30(10):733-41. Review
Van der Voort LF, Gilli F, Bertolotto A, Knol DL, Uitdehaag BM, Polman CH, Killestein J. (2010) Clinical effect of neutralizing antibodies to interferon beta that persist long after cessation of therapy for multiple sclerosis. Arch Neurol 67(4):402-7.
Gilli F, Lindberg RL, Valentino P, Marnetto F, Malucchi S, Sala A, Capobianco M, di Sapio A, Sperli F, Kappos L, Calogero RA, Bertolotto A. (2010) Learning from nature: pregnancy changes the expression of inflammation-related genes in patients with multiple sclerosis. PLoS One 29;5(1):e8962.
Before 2010
Marnetto F, Hellias B, Granieri L, Frau J, Patanella AK, Nytrova P, Sala A, Capobianco M, Gilli F, Bertolotto A. (2009) Western blot analysis for the detection of serum antibodies recognizing linear Aquaporin-4 epitopes in patients with Neuromyelitis Optica. J Neuroimmunol 10;217(1-2):74-9.
Bertolotto A. (2009) Implications of neutralising antibodies on therapeutic efficacy. J Neurol Sci 1;277 Suppl 1:S29-32. Review.
Gilli F, Valentino P, Caldano M, Granieri L, Capobianco M, Malucchi S, Sala A, Marnetto F, Bertolotto A. (2008) Expression and regulation of IFNalpha/beta receptor in IFNbeta-treated patients with multiple sclerosis. Neurology 9;71(24):1940-7.
Bertolotto A, Gilli F. Interferon-beta responders and non-responders. A biological approach. Neurol Sci. 2008 Sep;29 Suppl 2:S216-7. Review.
Gilli F, van Beers M, Marnetto F, Jiskoot W, Bertolotto A, Schellekens H. (2008)Development of a bioassay for quantification of neutralising antibodies against human interferon-beta in mouse sera. J Immunol Methods 31;336(2):119-26.
Malucchi S, Gilli F, Caldano M, Marnetto F, Valentino P, Granieri L, Sala A, Capobianco M, Bertolotto A. (2008)
Predictive markers for response to interferon therapy in patients with multiple sclerosis. Neurology 25;70(13 Pt 2):1119-27.
Bertolotto A, Sala A, Caldano M, Capobianco M, Malucchi S, Marnetto F, Gilli F. (2007) Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta. J Immunol Methods 321(1-2):19-31
Gilli F, Marnetto F, Caldano M, Valentino P, Granieri L, Di Sapio A, Capobianco M, Sala A, Malucchi S, Kappos L, Lindberg RLP, Bertolotto A. (2007) Anti-interferon-beta Neutralizing Activity is not Entirely Mediated by Antibodies. J Neuroimmunol 192(1-2):198-205
Gilli F, Hoffmann F, Sala A, Marnetto F, Caldano M, Valentino P, Kappos L, Bertolotto A,Lindberg RLP. (2007) Qualitative and quantitative analysis of antibody response against IFNb in patients with multiple sclerosis. Multiple Sclerosis 12(6):738-746
Gilli F, Marnetto F, Caldano S, Sala A, Malucchi S, Capobianco M, Bertolotto A. (2006) Biological markers of inteferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1. Multiple Sclerosis 12(1):47-57
Gilli F, Marnetto F, Stefanuto G, Rinaldi V, Farinazzo F, Caldano M, Malucchi S, Capobianco M, Sala A, Bertolotto A. (2005) Comparison of three different PCR assays for the evaluation of IFNbeta Biological Activity in Multiple Sclerosis Patients. Mol Diag 8(3):185-194
Gilli F, Marnetto F, Caldano M, Sala A, Malucchi S, Di Sapio A, Capobianco M, Bertolotto A. (2005) Biological Responsiveness to First Injections of Interferon-Beta in Patients With Multiple Sclerosis. J Neuroimmunol 158(1-2):195-203
Gilli F, Bertolotto A, Sala A, Hoffmann F, Capobianco M, Malucchi S, Glass T, Kappos L, Lindberg RLP, Leppert D. (2004) Neutralising antibodies against IFN-beta in MS: antagonisation of IFNbeta mediated suppression of MMPs. Brain 127(Pt2):259-268
Bertolotto A. (2004) Neutralizing antibodies to interferon beta: implications for the management of multiple sclerosis. Curr Opin Neurol 17(3):241-246. Review
Bertolotto A, Sala A, Malucchi S, Marnetto F, Caldano M, Di Sapio A, Capobianco M, Gilli F. (2004) The Biological Activity of IFNbetas in MS Patients is Affected by Treatment Regimen and Neutralizing Antibodies. J Neurol Neurosurg Psychiatry 75(9):1294-1299
Malucchi S, Sala A, Gilli F, Bottero R, Di Sapio A, Capobianco M, Bertolotto A. (2004) Neutralizing Antibodies Reduce the Clinical Efficacy of Interferon Beta Products during the Treatment of Multiple Sclerosis. Neurology 62(11):2031-2037
Milano E, Di Sapio A, Malucchi S, Capobianco M, Bottero R, Sala A, Gilli F, Bertolotto A. (2003) Neuromyelitis optica: importance of cerebrospinal fluid examination during Relapse. Neurol Sci 3:130-133
Bertolotto A, Gilli F, Sala A, Capobianco M, Malucchi S, Milano E, Melis F, Marnetto F, Lindberg RLP, Bottero R, Di Sapio A, Giordana MT. (2003) Persistent Neutralizing Antibodies abolish IFN-beta bioavailability in MS patients. Neurology 60:634-639
Bertolotto A, Malucchi S, Sala A, Orefice G, Carrieri PB, Capobianco M, Milano E, Melis F, Giordana MT. (2002) Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory. J Neurol Neurosurg Psychiatry 73(2):148-153
Gilli F, Sala A, Bancone C, Salacone P, Gallo M, Gaia E, Bertolotto A. (2002) IFN-alpha bioavailability evaluation by MxA mRNA quantification in HCV patients. J Immunol Meth 262:187-190
